Pharmacodynamic data on fosfomycin in underweight infants during the neonatal period
- PMID: 832519
- DOI: 10.1159/000222051
Pharmacodynamic data on fosfomycin in underweight infants during the neonatal period
Abstract
A study was made of the blood levels, half-life and elimination of fosfomycin in two groups of underweight infants during the 1st to 3rd days of life and after 3-4 weeks. The test dose was 50 mg/kg i.v., administered in a single dose. The times at which the blood was controlled were 5 min, 1, 3, 6, 9 and 24 h; and 0-24 h for the urine. All samples were evaluated by the microbiological method of diffusion in plate. The results obtained indicate that the elimination of fosfomycin after 24 h is slower and occurs in smaller quantities in the group of infants 1-3 days old than in the group of 3- to 4-week-old infants, the half-life of the antibiotic being 7 and 4.9 h, respectively.
Similar articles
-
Pharmacokinetics of fosfomycin.Chemotherapy. 1977;23 Suppl 1:141-51. doi: 10.1159/000222040. Chemotherapy. 1977. PMID: 832510
-
Pharmacokinetic study of fosfomycin and its bioavailability.Chemotherapy. 1977;23 Suppl 1:159-74. doi: 10.1159/000222043. Chemotherapy. 1977. PMID: 832511
-
Pharmacokinetics of fosfomycin in hemodialyzed patients.Clin Nephrol. 1985 May;23(5):218-21. Clin Nephrol. 1985. PMID: 4006330
-
Fosfomycin: an old--new antibiotic.Clin Microbiol Infect. 2012 Jan;18(1):4-7. doi: 10.1111/j.1469-0691.2011.03636.x. Epub 2011 Sep 13. Clin Microbiol Infect. 2012. PMID: 21914036 Review.
-
Structure and mechanism of enzymes involved in biosynthesis and breakdown of the phosphonates fosfomycin, dehydrophos, and phosphinothricin.Arch Biochem Biophys. 2011 Jan 1;505(1):13-21. doi: 10.1016/j.abb.2010.09.012. Epub 2010 Sep 18. Arch Biochem Biophys. 2011. PMID: 20854789 Free PMC article. Review.
Cited by
-
IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis.J Antimicrob Chemother. 2021 Jun 18;76(7):1855-1864. doi: 10.1093/jac/dkab083. J Antimicrob Chemother. 2021. PMID: 33855449 Free PMC article. Clinical Trial.
-
A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.Clin Pharmacokinet. 2011 Aug;50(8):493-503. doi: 10.2165/11592670-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21740073 Review.
-
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.Paediatr Drugs. 2021 Sep;23(5):465-484. doi: 10.1007/s40272-021-00465-z. Epub 2021 Aug 26. Paediatr Drugs. 2021. PMID: 34435316 Free PMC article. Review.
-
The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.Drugs. 2017 Jun;77(9):941-950. doi: 10.1007/s40265-017-0745-x. Drugs. 2017. PMID: 28456943 Review.
-
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.CPT Pharmacometrics Syst Pharmacol. 2024 Mar;13(3):464-475. doi: 10.1002/psp4.13097. Epub 2024 Jan 3. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38108548 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources